GlassScriptPhysician profile
Eugene Sapozhnikov
NPI 1164488094
$5,639.05
in general payments reported to CMS, 2019-2025
33 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $337 · 2021: $446 · 2022: $133 · 2023: $1,388 · 2024: $1,101 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,820 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,819.93 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,415.15 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $858.99 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $533.96 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $416.02 | 2019-2025 | |
| Janssen Biotech, INC. | $391.25 | 2019-2024 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $230.21 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $170.95 | 2023-2024 | Linzess |
| Ardelyx, INC. | $153.65 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $145.74 | 2019-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $144.51 | 2022-2024 | Ocaliva |
| Celgene Corporation | $136.62 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $127.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $120.30 | 2023-2025 | Sucraid |
| Pfizer INC. | $97.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $90.31 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $80.86 | 2024-2025 | Omvoh |
| Amag Pharmaceuticals, INC. | $57.58 | 2019-2020 | |
| Pentax of America, INC. | $56.15 | 2020-2025 | Pentax Medical, Inspira, C2 Cryoballoon |
| Novo Nordisk INC | $54.61 | 2025 | Wegovy |
| Allergan, INC. | $50.57 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $49.80 | 2023 | |
| Braintree Laboratories, INC. | $36.34 | 2024 | Sutab |
| Shionogi INC | $33.08 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $30.49 | 2024 | Iqirvo |
| Aimmune Therapeutics, INC. | $26.67 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $23.22 | 2024 | Dupixent |
| Alfasigma USA, INC. | $23.07 | 2020 | |
| Alnylam Pharmaceuticals INC. | $21.12 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.24 | 2024 | Cyltezo |
| Amgen INC. | $16.49 | 2025 | |
| Redhill Biopharma INC. | $15.18 | 2021 | |
| Ucb, INC. | $11.96 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Sapozhnikov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.